Advanced Fluid Management Solutions for Cardiorenal Care

Delivering Innovative Fluid Management Solutions to Improve Patient Outcomes

Manage Your Cardiorenal Patients Safely and Effectively

When traditional care falls short, clinicians need proven, predictable solutions. Nuwellis provides cost-effective and workflow-friendly technology backed by comprehensive clinical support.

View Our Solution Contact

Clinical Excellence in Ultrafiltration

Decades of clinical evidence show how our precise cardiorenal therapy improves patient outcomes.

 

65 +

Clinical Studies

20 +

Years of Data

14 .58

Liters of Fluid Removed on Average

Read the Clinical Evidence

What to do When Diuretics Fail

A Trusted Approach to Managing Fluid When Diuretics Aren’t Enough

Precision fluid removal with Aquadex ultrafiltration guides predictable decongestion and protects heart–kidney function.

Precise

Precisely and consistently remove the exact amount of isotonic fluid (not just water), with an ultrafiltration system proven to deliver predictable results.

Flexible

Flexible, gentle, and tailored fluid management therapy for each patient’s individual needs.

Impactful

Clinically proven to reduce readmissions, complications, and costs.⁵

Programmatic Fluid Management

An Established Solution to Fluid Management

Fluid overload isn’t typically a one-time event. Cardiac patients require ongoing monitoring, support, and tailored treatment, and critical care patients may need pre-operative and post-operative fluid management.

That’s why the Nuwellis team of clinical experts will be with you every step of the way.

Schedule a Demo Access Resources

The Aquadex system has been studied in more patients than any other ultrafiltration system.¹

81 %

Reduction in Hospitalizations²

69 %

Decrease in Hospitalization Days³

53 %

Reduction in Readmission Risk vs. Diuretics⁴

Read The Clinical Evidence

Specialties Served:

  • Pre, Post-Operative, and ICU Fluid Management

  • Pediatric Patients Weighing 20kg or More With Various Kidney and Cardiac Conditions

  • Acute Kidney Injury, Chronic Kidney Disease, and Renal Failure

  • Heart Failure, Cardio-Renal Syndrome, and Pulmonary Edema

  • Earlier and Ongoing Chronic Disease Management

Company Profile

Nuwellis is a commercial-stage company focused on the Aquadex SmartFlow® System.

We deliver an integrated approach to cardiorenal management to intervene earlier, protect organ function, and support recovery in high-risk patients. Nuwellis is listed as NUWE on the Nasdaq Capital Market.

View investor Resources

How to get reimbursed for fluid management

Reimbursement Support

Navigating coverage shouldn’t be a barrier to better care. Nuwellis offers dedicated reimbursement resources to simplify adoption and support your team.

View Reimbursement Resources
1

Pinney, S, DeVita, M, Redfors, B. et al. Ultrafiltration for Management of Decompensated Heart Failure: A Reappraisal of AVOID-HF. J Am Coll Cardiol HF. null2025, 0 (0) .https://doi.org/10.1016/j.jchf.2024.11.018

2

Costanzo MR et al. JACC. 2012; 4(2): 95-105.

3

Bart BA et al. NEJM. 2012; 367: 2296-304.

4

Costanzo MR et al. JACC. 2007; 49(6): 675-83.

5

Bart BA et al. JACC. 2005; 46(11): 2043-47.

6

Costanzo MR et al. JACC. 2005; 46(11): 2047-52.

7

Jaski BE et al. J Card Fail. 2003; 9(3): 227-32.

8

Level of Evidence Grading Scale as Adapted from the Oxford Centre for Evidence-based Medicine (2009)